Expression of cytokines and chemokines in bullous pemphigoid

References

• Korman NJ. Bullous pemphigoid: the latest in diagnosis, prognosis, and therapy. Arch. Dermatol.134(9), 1137–1141 (1998).
   PubMedGoogle Scholar
• Sawamura D, Li K, Uitto J. 230-kD and 180-kD bullous pemphigoid antigens are distinct gene products. J. Invest. Dermatol.98(6), 942–943 (1992).
   PubMed Web of Science ®Google Scholar
• Iwata H, Kamio N, Aoyama Y et al. IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment. J. Invest. Dermatol.129(4), 919–926 (2009).
   PubMed Web of Science ®Google Scholar
• Sitaru C. Bullous pemphigoid: a prototypical antibody-mediated organ-specific autoimmune disease. J. Invest. Dermatol.129(4), 822–824 (2009).
   PubMed Web of Science ®Google Scholar
• Liu Z. Immunopathology of bullous pemphigoid, an autoimmune and inflammatory skin blistering disease. Keio J. Med.52(2), 128–133 (2003).
   PubMedGoogle Scholar
• Liu Z, Diaz LA. Bullous pemphigoid: end of the century overview. J. Dermatol.28(11), 647–650 (2001).
   PubMed Web of Science ®Google Scholar
• Liu Z, Giudice GJ, Zhou X et al. A major role for neutrophils in experimental bullous pemphigoid. J. Clin. Invest.100(5), 1256–1263 (1997).
   PubMed Web of Science ®Google Scholar
• De Pita O, Frezzolini A, Cianchini G, Ruffelli M, Teofoli P, Puddu P. T-helper 2 involvement in the pathogenesis of bullous pemphigoid, role of soluble CD30 (sCD30). Arch. Dermatol. Res.289(12), 667–670 (1997).
   PubMed Web of Science ®Google Scholar
• Inaoki M, Takehara K. Increased serum levels of interleukin (IL)-5, IL-6 and IL-8 in bullous pemphigoid. J. Dermatol. Sci.16(2), 152–157 (1998).
   PubMed Web of Science ®Google Scholar
• D’Auria L, Pietravalle M, Mastroianni A et al. IL-5 levels in the serum and blister fluid of patients with bullous pemphigoid: correlations with eosinophil cationic protein, RANTES, IgE and disease severity. Arch. Dermatol. Res.290(1–2), 25–27 (1998).
   PubMed Web of Science ®Google Scholar
• Ameglio F, D’Auria L, Bonifati C, Ferraro C, Mastroianni A, Giacalone B. Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensity. Br. J. Dermatol.138(4), 611–614 (1998).
   PubMed Web of Science ®Google Scholar
• D’Auria L, Mussi A, Bonifati C, Mastroianni A, Giacalone B, Ameglio F. Increased serum IL-6, TNF-α and IL-10 levels in patients with bullous pemphigoid: relationships with disease activity. J. Eur. Acad. Dermatol. Venereol.12(1), 11–15 (1999).
   PubMed Web of Science ®Google Scholar
• Giacalone B, D’Auria L, Bonifati C et al. Decreased interleukin-7 and transforming growth factor-β1 levels in blister fluids as compared to the respective serum levels in patients with bullous pemphigoid. Opposite behavior of TNF-α, interleukin-4 and interleukin-10. Exp. Dermatol.7(4), 157–161 (1998).
   PubMed Web of Science ®Google Scholar
• Brown LF, Harrist TJ, Yeo KT et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme. J. Invest. Dermatol.104(5), 744–749 (1995).
   PubMed Web of Science ®Google Scholar
• Schmidt E, Mittnacht A, Schomig H, Dummer R, Brocker EB, Zillikens D. Detection of IL-1 α, IL-1 β and IL-1 receptor antagonist in blister fluid of bullous pemphigoid. J. Dermatol. Sci.11(2), 142–147 (1996).
   PubMed Web of Science ®Google Scholar
• Grando SA, Glukhenky BT, Drannik GN, Epshtein EV, Kostromin AP, Korostash TA. Mediators of inflammation in blister fluids from patients with pemphigus vulgaris and bullous pemphigoid. Arch. Dermatol.125(7), 925–930 (1989).
   PubMed Web of Science ®Google Scholar
• Schmidt E, Bastian B, Dummer R, Tony HP, Brocker EB, Zillikens D. Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. Arch. Dermatol. Res.288(7), 353–357 (1996).
   PubMed Web of Science ®Google Scholar
• Schmidt E, Ambach A, Bastian B, Brocker EB, Zillikens D. Elevated levels of interleukin-8 in blister fluid of bullous pemphigoid compared with suction blisters of healthy control subjects. J. Am. Acad. Dermatol.34(2 Pt 1), 310–312 (1996).
   PubMed Web of Science ®Google Scholar
• Tamaki K, So K, Furuya T, Furue M. Cytokine profile of patients with bullous pemphigoid. Br. J. Dermatol.130(1), 128–129 (1994).
   PubMed Web of Science ®Google Scholar
• Salgame P, Abrams JS, Clayberger C et al. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science254(5029), 279–282 (1991).
   PubMed Web of Science ®Google Scholar
• Paliard X, de Waal Malefijt R, Yssel H et al. Simultaneous production of IL-2, IL-4, and IFN-γ by activated human CD4+ and CD8+ T cell clones. J. Immunol.141(3), 849–855 (1988).
   PubMed Web of Science ®Google Scholar
• Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin. Microbiol. Rev.9(4), 532–562 (1996).
   PubMed Web of Science ®Google Scholar
• Nakazawa M, Sugi N, Kawaguchi H, Ishii N, Nakajima H, Minami M. Predominance of type 2 cytokine-producing CD4+ and CD8+ cells in patients with atopic dermatitis. J. Allergy Clin. Immunol.99(5), 673–682 (1997).
   PubMed Web of Science ®Google Scholar
• Kaneko F, Minagawa T, Takiguchi Y, Suzuki M, Itoh N. Role of cell-mediated immune reaction in blister formation of bullous pemphigoid. Dermatology184(1), 34–39 (1992).
   PubMed Web of Science ®Google Scholar
• Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med.179(6), 1895–1902 (1994).
   PubMed Web of Science ®Google Scholar
• Nakamaru Y, Oridate N, Nishihira J, Takagi D, Furuta Y, Fukuda S. Macrophage migration inhibitory factor (MIF) contributes to the development of allergic rhinitis. Cytokine31(2), 103–108 (2005).
   PubMed Web of Science ®Google Scholar
• Shimizu T. Role of macrophage migration inhibitory factor (MIF) in the skin. J. Dermatol. Sci.37(2), 65–73 (2005).
   PubMed Web of Science ®Google Scholar
• Asano Y, Makino T, Norisugi O et al. Macrophage migration inhibitory factor (MIF) in bullous pemphigoid. J. Dermatol. Sci.49(1), 95–97 (2008).
   PubMed Web of Science ®Google Scholar
• Donnelly SC, Haslett C, Reid PT et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat. Med.3(3), 320–323 (1997).
   PubMed Web of Science ®Google Scholar
• Mackay CR. Chemokines: immunology’s high impact factors. Nat. Immunol.2(2), 95–101 (2001).
   PubMed Web of Science ®Google Scholar
• Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol.18, 593–620 (2000).
   PubMed Web of Science ®Google Scholar
• Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol.25(2), 75–84 (2004).
   PubMed Web of Science ®Google Scholar
• Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity16(1), 1–4 (2002).
   PubMed Web of Science ®Google Scholar
• D’Ambrosio D, Iellem A, Bonecchi R et al. Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J. Immunol.161(10), 5111–5115 (1998).
   PubMed Web of Science ®Google Scholar
• Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science277(5334), 2005–2007 (1997).
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med.187(6), 875–883 (1998).
   PubMed Web of Science ®Google Scholar
• Weng Y, Siciliano SJ, Waldburger KE et al. Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J. Biol. Chem.273(29), 18288–18291 (1998).
   PubMed Web of Science ®Google Scholar
• Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguri P, Farber JM. Human Mig chemokine: biochemical and functional characterization. J. Exp. Med.182(5), 1301–1314 (1995).
   PubMed Web of Science ®Google Scholar
• Bonecchi R, Bianchi G, Bordignon PP et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med.187(1), 129–134 (1998).
   PubMed Web of Science ®Google Scholar
• Koch AE, Kunkel SL, Harlow LA et al. Macrophage inflammatory protein-1 a. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. J Clin. Invest.93(3), 921–928 (1994).
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Adams DH, Hubscher S, Hirano H, Siebenlist U, Shaw S. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 β. Nature361(6407), 79–82 (1993).
   PubMed Web of Science ®Google Scholar
• Nickel R, Beck LA, Stellato C, Schleimer RP. Chemokines and allergic disease. J. Allergy Clin. Immunol.104(4 Pt 1), 723–742 (1999).
   PubMed Web of Science ®Google Scholar
• Godiska R, Chantry D, Raport CJ et al. Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J. Exp. Med.185(9), 1595–1604 (1997).
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity12(2), 121–127 (2000).
   PubMed Web of Science ®Google Scholar
• Gerber BO, Zanni MP, Uguccioni M et al. Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils. Curr. Biol.7(11), 836–843 (1997).
   PubMed Web of Science ®Google Scholar
• Ponath PD, Qin S, Post TW et al. Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J. Exp. Med.183(6), 2437–2448 (1996).
   PubMed Web of Science ®Google Scholar
• Wakugawa M, Nakamura K, Hino H et al. Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia. Br. J. Dermatol.143(1), 112–116 (2000).
   PubMed Web of Science ®Google Scholar
• Shrikhande M, Hunziker T, Braathen LR, Pichler WJ, Dahinden CA, Yawalkar N. Increased coexpression of eotaxin and interleukin 5 in bullous pemphigoid. Acta Derm. Venereol.80(4), 277–280 (2000).
   PubMed Web of Science ®Google Scholar
• Frezzolini A, Teofoli P, Cianchini G et al. Increased expression of eotaxin and its specific receptor CCR3 in bullous pemphigoid. Eur. J. Dermatol.12(1), 27–31 (2002).
   PubMed Web of Science ®Google Scholar
• Kakinuma T, Wakugawa M, Nakamura K, Hino H, Matsushima K, Tamaki K. High level of thymus and activation-regulated chemokine in blister fluid and sera of patients with bullous pemphigoid. Br. J. Dermatol.148(2), 203–210 (2003).
   PubMed Web of Science ®Google Scholar
• Frezzolini A, Cianchini G, Ruffelli M, Cadoni S, Puddu P, De Pita O. Interleukin-16 expression and release in bullous pemphigoid. Clin. Exp. Immunol.137(3), 595–600 (2004).
   PubMed Web of Science ®Google Scholar
• Gounni Abdelilah S, Wellemans V, Agouli M et al. Increased expression of Th2-associated chemokines in bullous pemphigoid disease. Role of eosinophils in the production and release of these chemokines. Clin. Immunol.120(2), 220–231 (2006).
   PubMed Web of Science ®Google Scholar
• Echigo T, Hasegawa M, Shimada Y, Inaoki M, Takehara K, Sato S. Both Th1 and Th2 chemokines are elevated in sera of patients with autoimmune blistering diseases. Arch. Dermatol. Res.298(1), 38–45 (2006).
   PubMed Web of Science ®Google Scholar
• Nakashima H, Fujimoto M, Asashima N et al. Serum chemokine profile in patients with bullous pemphigoid. Br. J. Dermatol.156(3), 454–459 (2007).
   PubMed Web of Science ®Google Scholar
• Pan J, Kunkel EJ, Gosslar U et al. A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. J. Immunol.165(6), 2943–2949 (2000).
   PubMed Web of Science ®Google Scholar
• Kagami S, Kakinuma T, Saeki H et al. Increased serum CCL28 levels in patients with atopic dermatitis, psoriasis vulgaris and bullous pemphigoid. J. Invest. Dermatol.124(5), 1088–1090 (2005).
   PubMed Web of Science ®Google Scholar
• Kodelja V, Muller C, Politz O, Hakij N, Orfanos CE, Goerdt S. Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 α with a Th2-associated expression pattern. J. Immunol.160(3), 1411–1418 (1998).
   PubMed Web of Science ®Google Scholar
• Hieshima K, Imai T, Baba M et al. A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 α/LD78 α and chemotactic for T lymphocytes, but not for monocytes. J. Immunol.159(3), 1140–1149 (1997).
   PubMed Web of Science ®Google Scholar
• Gunther C, Carballido-Perrig N, Kopp T, Carballido JM, Pfeiffer C. CCL18 is expressed in patients with bullous pemphigoid and parallels disease course. Br. J. Dermatol.160(4), 747–755 (2009).
   PubMed Web of Science ®Google Scholar
• Proost P, Wuyts A, Van Damme J. Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1. J. Leukoc. Biol.59(1), 67–74 (1996).
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Robinson EA, Tanaka S, Appella E, Kuratsu J, Leonard EJ. Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J. Exp. Med.169(4), 1449–1459 (1989).
   PubMed Web of Science ®Google Scholar
• Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat. Rev. Drug Discov.5(3), 235–246 (2006).
   PubMed Web of Science ®Google Scholar
• Mackay F, Schneider P, Rennert P, Browning BAFF AND APRIL: a tutorial on B cell survival. Annu. Rev. Immunol.21, 231–264 (2003).
   PubMed Web of Science ®Google Scholar
• Mackay F, Ambrose C. The TNF family members BAFF and APRIL: the growing complexity. Cytokine Growth Factor Rev.14(3–4), 311–324 (2003).
   PubMed Web of Science ®Google Scholar
• Moore PA, Belvedere O, Orr A et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science285(5425), 260–263 (1999).
   PubMed Web of Science ®Google Scholar
• Ramanujam M, Wang X, Huang W et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J. Clin. Invest.116(3), 724–734 (2006).
   PubMed Web of Science ®Google Scholar
• Asashima N, Fujimoto M, Watanabe R et al. Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris. Br. J. Dermatol.155(2), 330–336 (2006).
   PubMed Web of Science ®Google Scholar
• Watanabe R, Fujimoto M, Yazawa N et al. Increased serum levels of a proliferation-inducing ligand in patients with bullous pemphigoid. J. Dermatol. Sci.46(1), 53–60 (2007).
   PubMed Web of Science ®Google Scholar
• Budinger L, Borradori L, Yee C et al. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J. Clin. Invest.102(12), 2082–2089 (1998).
   PubMed Web of Science ®Google Scholar